Details of the Drug

General Information of Drug (ID: DM3NXRU)

Drug Name

Timolol

Synonyms

Aquanil; Betim; Betimol; Blocadren; Istalol; Optimol; Proflax; TIM; Temserin; Tenopt; Timacar; Timololum; Timopic; Timoptol; Timolol GFS; Timolol [USAN]; Timoptic OcuDose; Apo-Timol; Apo-Timop; Betimol (TN); Blocadren (TN); Istalol (TN); MK-950; Novo-Timol; Nu-Timolol; Phoxal-timolol; Tim-AK; Timolol (INN); Timolol (TN); Timololum [INN-Latin]; Timoptic (TN); Timoptic-XE; Apo-Timol (TN); Apo-Timop (TN); Gen-Timolol (TN); L-714,465; Nu-Timolol (TN); PMS-Timolol (TN); Phoxal-timolol (TN); Tim-AK (TN); Timoptic OcuDose. (TN); Timoptic-XE (TN); S(-)-Timolol maleate; Timolol Maleate, (1:1) Salt; S-(-)-3-(3-tert-Butylamino-2-hydroxypropoxy)-4-morpholino-1,2,5-thiadiazole; (-)-3-Morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole; (2S)-1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol; (2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol; (2S)-1-[(1,1-dimethylethyl)amino]-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol; (S)-1-(1,1-(Dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol; (S)-1-(tert-Butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)propan-2-ol; (S)-timolol

Indication

Disease Entry	ICD 11	Status	REF
High blood pressure	BA00	Approved	[1], [2]

Therapeutic Class

Antiarrhythmic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

316.42

Topological Polar Surface Area (xlogp)

1.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 6.46 mcgh/L [3]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 1.14 mcg/L [3]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 15 min [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability: The bioavailability of drug is 78.0 +/- 24.5% [3]
Clearance: The renal clearance of drug is 97.2 +/- 10.1 mL/min [5]
Elimination: 15% of drug is excreted from urine in the unchanged form [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 2.9 +/- 0.3 hours [6]
Metabolism: The drug is metabolized via the liver [6]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 3.1603 micromolar/kg/day [7]
Unbound Fraction: The unbound fraction of drug in plasma is 0.9% [8]
Vd: The volume of distribution (Vd) of drug is 1.3-1.7 L/kg [9]
Water Solubility: The ability of drug to dissolve in water is measured as 2.74 mg/mL [4]

Chemical Identifiers

Formula: C13H24N4O3S
IUPAC Name: (2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
Canonical SMILES: CC(C)(C)NC[C@@H](COC1=NSN=C1N2CCOCC2)O
InChI: InChI=1S/C13H24N4O3S/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17/h10,14,18H,4-9H2,1-3H3/t10-/m0/s1
InChIKey: BLJRIMJGRPQVNF-JTQLQIEISA-N

Cross-matching ID

PubChem CID: 33624
ChEBI ID: CHEBI:9599
CAS Number: 26839-75-8
DrugBank ID: DB00373
TTD ID: D05UVD
VARIDT ID: DR00900
INTEDE ID: DR1595
ACDINA ID: D00677

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-1 (ADRB1)	TTR6W5O	ADRB1_HUMAN	Antagonist	[10], [11], [12]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)_{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[14]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[15]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Timolol

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Ethacrynic acid	DM60QMR	Moderate	Increased risk of hypertriglyceridemia by the combination of Timolol and Ethacrynic acid.	Essential hypertension [BA00]	[51]
Bendroflumethiazide	DM7EVLC	Moderate	Increased risk of hyperglycemia by the combination of Timolol and Bendroflumethiazide.	Essential hypertension [BA00]	[51]
Phenoxybenzamine	DM8KSQH	Moderate	Additive hypotensive effects by the combination of Timolol and Phenoxybenzamine.	Essential hypertension [BA00]	[52]
Nicardipine	DMCDYW7	Moderate	Increased risk of cardiac depression by the combination of Timolol and Nicardipine.	Essential hypertension [BA00]	[53]
Benzthiazide	DMQWZ0H	Moderate	Increased risk of ventricular arrhythmias by the combination of Timolol and Benzthiazide.	Essential hypertension [BA00]	[51]
-----------

Coadministration of a Drug Treating the Disease Different from Timolol (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Scopolamine	DMOM8AL	Moderate	Antagonize the effect of Timolol when combined with Scopolamine.	Addictive disorder [6C50-6C5Z]	[54]
Tripelennamine	DMZBU15	Moderate	Decreased metabolism of Timolol caused by Tripelennamine mediated inhibition of CYP450 enzyme.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[55]
Bepridil	DM0RKS4	Moderate	Increased risk of cardiac depression by the combination of Timolol and Bepridil.	Angina pectoris [BA40]	[53]
Dronedarone	DMA8FS5	Moderate	Increased risk of bradycardia by the combination of Timolol and Dronedarone.	Angina pectoris [BA40]	[56]
Nifedipine	DMSVOZT	Moderate	Increased risk of cardiac depression by the combination of Timolol and Nifedipine.	Angina pectoris [BA40]	[53]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Timolol caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[57]
Promazine	DMZAL7W	Moderate	Additive hypotensive effects by the combination of Timolol and Promazine.	Appearance/behaviour symptom [MB23]	[58]
Zileuton	DMVRIC2	Moderate	Decreased metabolism of Timolol caused by Zileuton.	Asthma [CA23]	[59]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Timolol and Cariprazine.	Bipolar disorder [6A60]	[58]
Secobarbital	DM14RF5	Moderate	Increased metabolism of Timolol caused by Secobarbital mediated induction of CYP450 enzyme.	Chronic insomnia [7A00]	[60]
Atracurium	DM42HXN	Moderate	Additive neuromuscular blocking effects by the combination of Timolol and Atracurium.	Corneal disease [9A76-9A78]	[61]
Mivacurium	DM473VD	Moderate	Additive neuromuscular blocking effects by the combination of Timolol and Mivacurium.	Corneal disease [9A76-9A78]	[61]
Pancuronium	DMB0VY8	Moderate	Additive neuromuscular blocking effects by the combination of Timolol and Pancuronium.	Corneal disease [9A76-9A78]	[61]
Tubocurarine	DMBZIVP	Moderate	Additive neuromuscular blocking effects by the combination of Timolol and Tubocurarine.	Corneal disease [9A76-9A78]	[61]
Nimodipine	DMQ0RKZ	Moderate	Increased risk of cardiac depression by the combination of Timolol and Nimodipine.	Coronary vasospastic disease [BA85]	[53]
Pasireotide	DMHM7JS	Moderate	Increased risk of atrioventricular block by the combination of Timolol and Pasireotide.	Cushing syndrome [5A70]	[62]
Sertraline	DM0FB1J	Moderate	Decreased metabolism of Timolol caused by Sertraline mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[63]
Fluoxetine	DM3PD2C	Moderate	Decreased metabolism of Timolol caused by Fluoxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[63]
Paroxetine	DM5PVQE	Moderate	Decreased metabolism of Timolol caused by Paroxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[63]
Duloxetine	DM9BI7M	Moderate	Decreased metabolism of Timolol caused by Duloxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[64]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Timolol and OPC-34712.	Depression [6A70-6A7Z]	[58]
Hyoscyamine	DM804UR	Moderate	Antagonize the effect of Timolol when combined with Hyoscyamine.	Digestive system disease [DE2Z]	[65]
Mepenzolate	DM8YU2F	Moderate	Antagonize the effect of Timolol when combined with Mepenzolate.	Digestive system disease [DE2Z]	[54]
Oxybutynine	DMJPBAX	Moderate	Antagonize the effect of Timolol when combined with Oxybutynine.	Discovery agent [N.A.]	[54]
Trihexyphenidyl	DMB19L8	Moderate	Antagonize the effect of Timolol when combined with Trihexyphenidyl.	Dystonic disorder [8A02]	[54]
Fenfluramine	DM0762O	Moderate	Decreased metabolism of Timolol caused by Fenfluramine mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[55]
Primidone	DM0WX6I	Moderate	Increased metabolism of Timolol caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[60]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Timolol caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[66]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Timolol caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[60]
Diphenhydramine	DMKQTBA	Moderate	Decreased metabolism of Timolol caused by Diphenhydramine mediated inhibition of CYP450 enzyme.	Episodic vestibular syndrome [AB31]	[55]
Phenylephrine	DMZHUO5	Moderate	Additive hypertensive effects by the combination of Timolol and Phenylephrine.	Faecal incontinence [ME07]	[67]
Mirabegron	DMS1GYT	Moderate	Decreased metabolism of Timolol caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[68]
Tolterodine	DMSHPW8	Moderate	Antagonize the effect of Timolol when combined with Tolterodine.	Functional bladder disorder [GC50]	[54]
Darifenacin	DMWXLYZ	Moderate	Decreased metabolism of Timolol caused by Darifenacin mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[69]
Terbinafine	DMI6HUW	Moderate	Decreased metabolism of Timolol caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[70]
Propantheline	DM2EN6G	Moderate	Additive CNS depression effects by the combination of Timolol and Propantheline.	Gastric ulcer [DA60]	[65]
Cimetidine	DMH61ZB	Moderate	Decreased metabolism of Timolol caused by Cimetidine mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[71]
Spironolactone	DM2AQ5N	Moderate	Increased risk of hypertriglyceridemia by the combination of Timolol and Spironolactone.	Heart failure [BD10-BD1Z]	[51]
Triamterene	DM2HU9I	Moderate	Increased risk of hypertriglyceridemia by the combination of Timolol and Triamterene.	Heart failure [BD10-BD1Z]	[51]
Prazosin	DMCD9YG	Moderate	Additive hypotensive effects by the combination of Timolol and Prazosin.	Heart failure [BD10-BD1Z]	[52]
Chlorothiazide	DMLHESP	Moderate	Increased risk of hyperglycemia by the combination of Timolol and Chlorothiazide.	Heart failure [BD10-BD1Z]	[51]
Furosemide	DMMQ8ZG	Moderate	Increased risk of hypertriglyceridemia by the combination of Timolol and Furosemide.	Heart failure [BD10-BD1Z]	[51]
Bumetanide	DMRV7H0	Moderate	Increased risk of hypertriglyceridemia by the combination of Timolol and Bumetanide.	Heart failure [BD10-BD1Z]	[51]
Hydroflumethiazide	DMVPUQI	Moderate	Increased risk of hyperglycemia by the combination of Timolol and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[51]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Timolol caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[72]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Timolol caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[55]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Timolol caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[73]
Ritonavir	DMU764S	Moderate	Decreased metabolism of Timolol caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[74]
Cinacalcet	DMCX0K3	Moderate	Decreased metabolism of Timolol caused by Cinacalcet mediated inhibition of CYP450 enzyme.	Hyper-parathyroidism [5A51]	[65]
Nisoldipine	DM7ISKJ	Moderate	Increased risk of cardiac depression by the combination of Timolol and Nisoldipine.	Hypertension [BA00-BA04]	[53]
Levamlodipine	DM92S6N	Moderate	Increased risk of cardiac depression by the combination of Timolol and Levamlodipine.	Hypertension [BA00-BA04]	[53]
Doxazosin	DM9PLRH	Moderate	Additive hypotensive effects by the combination of Timolol and Doxazosin.	Hypertension [BA00-BA04]	[52]
Verapamil	DMA7PEW	Major	Increased risk of cardiac depression by the combination of Timolol and Verapamil.	Hypertension [BA00-BA04]	[53]
Amlodipine	DMBDAZV	Moderate	Increased risk of cardiac depression by the combination of Timolol and Amlodipine.	Hypertension [BA00-BA04]	[53]
Indapamide	DMGN1PW	Moderate	Increased risk of hypertriglyceridemia by the combination of Timolol and Indapamide.	Hypertension [BA00-BA04]	[51]
Trichlormethiazide	DMHAQCO	Moderate	Increased risk of hypertriglyceridemia by the combination of Timolol and Trichlormethiazide.	Hypertension [BA00-BA04]	[51]
Felodipine	DMOSW35	Moderate	Increased risk of cardiac depression by the combination of Timolol and Felodipine.	Hypertension [BA00-BA04]	[53]
Hydralazine	DMU8JGH	Minor	Decreased metabolism of Timolol caused by Hydralazine mediated interference with first-pass metabolism.	Hypertension [BA00-BA04]	[75]
Hydrochlorothiazide	DMUSZHD	Moderate	Increased risk of hyperglycemia by the combination of Timolol and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[51]
Clevidipine butyrate	DMW4M97	Moderate	Increased risk of cardiac depression by the combination of Timolol and Clevidipine butyrate.	Hypertension [BA00-BA04]	[53]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Timolol caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[76]
Belladonna	DM2RBWK	Moderate	Antagonize the effect of Timolol when combined with Belladonna.	Infectious gastroenteritis/colitis [1A40]	[54]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Timolol caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[77]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Timolol caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[60]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Timolol and Propiomazine.	Insomnia [7A00-7A0Z]	[58]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Timolol and ITI-007.	Insomnia [7A00-7A0Z]	[58]
Clidinium	DMUMQZ0	Moderate	Antagonize the effect of Timolol when combined with Clidinium.	Irritable bowel syndrome [DD91]	[54]
Dicyclomine	DMZSDGX	Moderate	Antagonize the effect of Timolol when combined with Dicyclomine.	Irritable bowel syndrome [DD91]	[54]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Timolol caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[54]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Timolol caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[78]
Lumefantrine	DM29GAD	Moderate	Decreased metabolism of Timolol caused by Lumefantrine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[65]
Halofantrine	DMOMK1V	Moderate	Decreased metabolism of Timolol caused by Halofantrine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[55]
Chloroquine	DMSI5CB	Minor	Decreased metabolism of Timolol caused by Chloroquine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[79]
Hydroxychloroquine	DMSIVND	Moderate	Decreased metabolism of Timolol caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[55]
Quinine	DMSWYF5	Moderate	Decreased metabolism of Timolol caused by Quinine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[55]
Primaquine	DMWQ16I	Moderate	Decreased metabolism of Timolol caused by Primaquine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[55]
Vemurafenib	DM62UG5	Moderate	Decreased metabolism of Timolol caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[80]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Timolol due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[62]
Panobinostat	DM58WKG	Moderate	Decreased metabolism of Timolol caused by Panobinostat mediated inhibition of CYP450 enzyme.	Multiple myeloma [2A83]	[81]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Timolol and Thalidomide.	Multiple myeloma [2A83]	[65]
Siponimod	DM2R86O	Major	Increased risk of atrioventricular block by the combination of Timolol and Siponimod.	Multiple sclerosis [8A40]	[65]
Fingolimod	DM5JVAN	Major	Increased risk of atrioventricular block by the combination of Timolol and Fingolimod.	Multiple sclerosis [8A40]	[82]
Ozanimod	DMT6AM2	Moderate	Increased risk of bradycardia by the combination of Timolol and Ozanimod.	Multiple sclerosis [8A40]	[83]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Timolol caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[54]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Timolol caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[84]
Prochlorperazine	DM53SRA	Moderate	Additive hypotensive effects by the combination of Timolol and Prochlorperazine.	Nausea/vomiting [MD90]	[58]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Timolol and Promethazine.	Nausea/vomiting [MD90]	[58]
Rolapitant	DM8XP26	Moderate	Decreased metabolism of Timolol caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[85]
Cyclizine	DM9G7BS	Moderate	Decreased metabolism of Timolol caused by Cyclizine mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[55]
Metoclopramide	DMFA5MY	Moderate	Decreased metabolism of Timolol caused by Metoclopramide mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[55]
Bupropion	DM5PCS7	Moderate	Decreased metabolism of Timolol caused by Bupropion mediated inhibition of CYP450 enzyme.	Nicotine use disorder [6C4A]	[86]
Lorcaserin	DMG6OYJ	Moderate	Decreased metabolism of Timolol caused by Lorcaserin mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[87]
Dexfenfluramine	DMJ7YDS	Moderate	Decreased metabolism of Timolol caused by Dexfenfluramine mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[55]
Metolazone	DMB39LO	Moderate	Increased risk of ventricular arrhythmias by the combination of Timolol and Metolazone.	Oedema [MG29]	[51]
Polythiazide	DMCH80F	Moderate	Increased risk of hypertriglyceridemia by the combination of Timolol and Polythiazide.	Oedema [MG29]	[51]
Dextropropoxyphene	DM23HCX	Moderate	Decreased metabolism of Timolol caused by Dextropropoxyphene mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[88]
Biperiden	DME78OA	Moderate	Additive CNS depression effects by the combination of Timolol and Biperiden.	Parkinsonism [8A00]	[54]
Procyclidine	DMHFJDT	Moderate	Additive CNS depression effects by the combination of Timolol and Procyclidine.	Parkinsonism [8A00]	[54]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Timolol caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[89]
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Timolol and Terazosin.	Prostate hyperplasia [GA90]	[52]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Timolol and Silodosin.	Prostate hyperplasia [GA90]	[52]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Timolol and Levomepromazine.	Psychotic disorder [6A20-6A25]	[58]
Fluphenazine	DMIT8LX	Moderate	Additive hypotensive effects by the combination of Timolol and Fluphenazine.	Psychotic disorder [6A20-6A25]	[58]
Celecoxib	DM6LOQU	Moderate	Decreased metabolism of Timolol caused by Celecoxib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[90]
Oxamniquine	DM2QDX1	Moderate	Decreased metabolism of Timolol caused by Oxamniquine mediated inhibition of CYP450 enzyme.	Schistosomiasis [1F86]	[55]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Timolol and Quetiapine.	Schizophrenia [6A20]	[58]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Timolol and Mesoridazine.	Schizophrenia [6A20]	[58]
Thioridazine	DM35M8J	Moderate	Additive hypotensive effects by the combination of Timolol and Thioridazine.	Schizophrenia [6A20]	[58]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Timolol and Aripiprazole.	Schizophrenia [6A20]	[58]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Timolol and Iloperidone.	Schizophrenia [6A20]	[58]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Timolol and Paliperidone.	Schizophrenia [6A20]	[58]
Loxapine	DM8AI9U	Moderate	Additive hypotensive effects by the combination of Timolol and Loxapine.	Schizophrenia [6A20]	[58]
Haloperidol	DM96SE0	Moderate	Additive hypotensive effects by the combination of Timolol and Haloperidol.	Schizophrenia [6A20]	[58]
Perphenazine	DMA4MRX	Moderate	Additive hypotensive effects by the combination of Timolol and Perphenazine.	Schizophrenia [6A20]	[58]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Timolol and Molindone.	Schizophrenia [6A20]	[58]
Chlorpromazine	DMBGZI3	Moderate	Additive hypotensive effects by the combination of Timolol and Chlorpromazine.	Schizophrenia [6A20]	[58]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Timolol and Thiothixene.	Schizophrenia [6A20]	[58]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Timolol and Trifluoperazine.	Schizophrenia [6A20]	[58]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Timolol and Risperidone.	Schizophrenia [6A20]	[58]
Amisulpride	DMSJVAM	Moderate	Increased risk of ventricular arrhythmias by the combination of Timolol and Amisulpride.	Schizophrenia [6A20]	[54]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Timolol and Asenapine.	Schizophrenia [6A20]	[58]
Pipecuronium	DM5F84A	Moderate	Additive neuromuscular blocking effects by the combination of Timolol and Pipecuronium.	Tonus and reflex abnormality [MB47]	[61]
Doxacurium	DMKE7L9	Moderate	Additive neuromuscular blocking effects by the combination of Timolol and Doxacurium.	Tonus and reflex abnormality [MB47]	[61]
Vecuronium	DMP0UK2	Moderate	Additive neuromuscular blocking effects by the combination of Timolol and Vecuronium.	Tonus and reflex abnormality [MB47]	[61]
Cisatracurium	DMUZPJ5	Moderate	Additive neuromuscular blocking effects by the combination of Timolol and Cisatracurium.	Tonus and reflex abnormality [MB47]	[61]
Rocuronium	DMY9BMK	Moderate	Additive neuromuscular blocking effects by the combination of Timolol and Rocuronium.	Tonus and reflex abnormality [MB47]	[61]
Atropine	DMEN6X7	Moderate	Antagonize the effect of Timolol when combined with Atropine.	Unspecific substance harmful effect [NE6Z]	[54]
Chlorpheniramine	DM5URA2	Moderate	Decreased metabolism of Timolol caused by Chlorpheniramine mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[55]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Timolol and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[58]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Timolol and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[91]
Propafenone	DMPIBJK	Moderate	Decreased metabolism of Timolol caused by Propafenone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[92]
Amiodarone	DMUTEX3	Moderate	Increased risk of bradycardia by the combination of Timolol and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[93]
-----------


⏷ Show the Full List of 132 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Benzalkonium chloride	E00536	21988052	Antimicrobial preservative; Penetration agent; Solubilizing agent; Surfactant
Carmellose sodium	E00625	Not Available	Disintegrant
Disodium hydrogenorthophosphate	E00283	24203	Buffering agent; Complexing agent
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Timolol 10 mg tablet	10 mg	Oral Tablet	Oral
Timolol 20 mg tablet	20 mg	Oral Tablet	Oral
Timolol 5 mg tablet	5 mg	Oral Tablet	Oral
Timolol Maleate eq 0.25% base solution	eq 0.25% base	Solution	Ophthalmic

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 565).
2	Brinzolamide/timolol fixed combination: a new ocular suspension for the treatment of open-angle glaucoma and ocular hypertension. Expert Opin Pharmacother. 2009 Aug;10(12):2015-24.
3	Korte JM, Kaila T, Saari KM: Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefes Arch Clin Exp Ophthalmol. 2002 Jun;240(6):430-5. doi: 10.1007/s00417-002-0462-2. Epub 2002 Apr 26.
4	BDDCS applied to over 900 drugs
5	Ishizaki T, Tawara K, Oyama Y, Nakaya H: Clinical pharmacologic observations on timolol. I. Disposition and effect in relation to plasma level in normal individuals. J Clin Pharmacol. 1978 Nov-Dec;18(11-12):511-8.
6	Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. Eur J Clin Pharmacol. 1983;24(2):227-30.
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
9	Link
10	Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006;23(12):977-95.
11	Blockade of beta-adrenergic receptors prevents amphetamine-induced behavioural sensitization in rats: a putative role of the bed nucleus of the str... Int J Neuropsychopharmacol. 2005 Dec;8(4):569-81.
12	A prospective study of the effects of prolonged timolol therapy on alpha- and beta-adrenoceptor and angiotensin II receptor mediated responses in normal subjects. Br J Clin Pharmacol. 1997 Mar;43(3):301-8.
13	Relationship between urinary sodium excretion and pioglitazone-induced edema. J Diabetes Investig. 2010 Oct 19;1(5):208-11.
14	Cardiac safety of ophthalmic timolol. Expert Opin Drug Saf. 2016 Nov;15(11):1549-1561.
15	Metabolism of ophthalmic timolol: new aspects of an old drug. Basic Clin Pharmacol Toxicol. 2011 May;108(5):297-303.
16	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
17	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
18	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
19	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
20	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
22	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
23	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
24	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
25	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
26	High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
27	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
28	Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
29	CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
30	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
31	Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
32	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
33	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
34	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
35	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
36	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
37	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
38	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
39	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
40	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
41	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
42	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
43	Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
44	Adrenergic activation of electrogenic K+ secretion in guinea pig distal colonic epithelium: involvement of beta1- and beta2-adrenergic receptors. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G269-77.
45	Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Crit Care Med. 1999 Feb;27(2):325-31.
46	Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
47	Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
48	beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):519-29.
49	beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25.
50	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
51	Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA "Nadolol in combination with indapamide and xipamide in resistant hypertensives." Eur J Clin Pharmacol 28 (1985): 29-33. [PMID: 3987783]
52	Chrysant SG "Experience with terazosin administered in combination with other antihypertensive agents." Am J Med 80 (1986): 55-61. [PMID: 2872808]
53	Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
54	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
55	Edeki TI, He HB, Wood AJJ "Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops: potential for oral-ophthalmic drug interaction." JAMA 274 (1995): 1611-3. [PMID: 7474246]
56	Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
57	Haglund K, Seideman P, Colliste P, Borg KO, von Bahr C "Influence of pentobarbital on metoprolol plasma levels." Clin Pharmacol Ther 26 (1979): 326-9. [PMID: 466926]
58	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
59	Product Information. Zylo Filmtab (zileuton). Abbott Pharmaceutical, Abbott Park, IL.
60	Branch RA, Herman RJ "Enzyme induction and beta-adrenergic receptor blocking drugs." Br J Clin Pharmacol 17 (1984): s77-84. [PMID: 6146342]
61	Chapple DJ, Clark JS, Hughes R "Interaction between atracurium and drugs used in anaesthesia." Br J Anaesth 55 Suppl 1 (1983): s17-22. [PMID: 6688011]
62	Canadian Pharmacists Association.
63	Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51. [PMID: 11304901]
64	Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
65	Cerner Multum, Inc. "Australian Product Information.".
66	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
67	Cass E, Kadar D, Stein HA "Hazards of phenylephrine topical medication in persons taking propranolol." Can Med Assoc J 120 (1979): 1261-2. [PMID: 221086]
68	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
69	Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
70	AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
71	Asgharnejad M, Powell R, Donn K, Danis M "The effect of cimetidine dose timing on oral propranolol kinetics in adults." Clin Pharmacol Ther 41 (1987): 203. [PMID: 3392231]
72	Kirch W, Rose I, Klingmann I, Pabst J, Ohnhaus EE "Interaction of bisoprolol with cimetidine and rifampicin." Eur J Clin Pharmacol 31 (1986): 59-62. [PMID: 2877885]
73	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
74	Product Information. Norvir (ritonavir). Abbott Pharmaceutical, Abbott Park, IL.
75	Amemiya M, Tabei K, Furuya H, Sakairi Y, Asano Y "Pharmacokinetics of carteolol in patients with impaired renal function." Eur J Clin Pharmacol 43 (1992): 417-21. [PMID: 1451723]
76	Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
77	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
78	Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
79	Lancaster DL, Adio RA, Tai KK, Simooya OO, Broadhead GD, Tucker GT, Lennard MS "Inhibition of metoprolol metabolism by chloroquine and other antimalarial drugs." J Pharm Pharmacol 42 (1990): 267-71. [PMID: 1974295]
80	Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
81	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
82	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
83	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
84	Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
85	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
86	Dufresne RL, Weber SS, Becker RE "Bupropion hydrochloride." Drug Intell Clin Pharm 18 (1984): 957-64. [PMID: 6439541]
87	Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
88	Janku I, Perlik F, Tkaczykova M, Brodanova M "Disposition kinetics and concentration-effect relationship of metipranolol in patients with cirrhosis and healthy subjects." Eur J Clin Pharmacol 42 (1992): 337-40. [PMID: 1349528]
89	Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
90	Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
91	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
92	Ahmad S "Metoprolol-induced delirium perpetuated by propafenone." Am Fam Physician 44 (1991): 1142,4. [PMID: 1927831]
93	Leor J, Levartowsky D, Sharon C, Farfel Z "Amiodarone and beta-adrenergic blockers: an interaction with metoprolol but not with atenolol." Am Heart J 16 (1988): 206-7. [PMID: 3394625]